Strategies to combat resistance: Focus on pharmacokinetics/pharmacodynamics with applications to β-lactams

Mumbai – 12 February 2011
Strategies to combat resistance:
Focus on pharmacokinetics/pharmacodynamics
with applications to \( \beta \)-lactams

Paul M. Tulkens
Unité de pharmacologie cellulaire et moléculaire
Université catholique de Louvain, Brussels, Belgium
&
International Society of Antiinfective Pharmacology

http://www.facm.ucl.ac.be  
http://www.isap.org
Antibiotic treatment: What does the clinician want?

- Best therapeutic effects
- No or minimal toxic effect

"The" drug
The ideal antibiotic...

The molecule brilliant and clear solutions

chemistry microbiology therapy

dentist's cure
Is the molecule always ideal?

the ideal molecule

brilliant and clear solutions

patient’s cure

chemistry microbiology therapy
Main causes of antibiotic failures...
Adapted from Pechère J.C., 1988, 1993, 1998

• False failures
  – erroneous diagnosis
  – underlying disease uninfluenced by antibiotics
  – unjustified lack of patience
  – inactivation of the antibiotic

• Patient related failures
  – compliance failure (broadly speaking)
  – inappropriate administration route (broadly speaking)
  – immunodepressed hosts

• Pharmacological failures
  – insufficient amount or drug inappropriately administered
  – no attention paid to pharmacodynamic parameters
  – in situ inactivation or lack of drainage

• Micro-organism related failures
  – wrong pathogen
  – resistance acquired during treatment
  – insufficient bactericidal activity
  – inoculum effect
In a nutshell ... so far ...

- **Microbiology parameters: MIC**!
- Pharmacodynamic parameters
- PK/PD as applied to beta-lactams: Time-above MIC
- The problems if you underdose
- Take home message
Microbiology

Identification

Susceptibility by static techniques

Drug concentration stays constant
What do I do in my country
(in relation to microbiology)?

• Survey the level of resistance of *P. aeruginosa* and *S. pneumoniae* from selected hospitals and relate it to therapy

• Examine the mechanisms of resistance acquisition (with special reference to efflux pumps)

Assess new antibiotics and novel approaches (immunotherapy)

• Examine the susceptibility to biocides

Supported by
1 Regional authorities and the Fund for Industrial Research
2 Fund for Scientific and Medical Research
3 Pharmaceutical Industry and small/medium enterprises
What is the situation at day 0?

MIC (mg/L : 0.0156 to 512 mg/L)

Riou et al. IJAA 2010; 36:513-522
What is the situation at day 0?

Know what YOUR distributions are!

MIC (mg/L : 0.0156 to 512 mg/L)

Riou et al. IJAA 2010; 36:513-522
Moving on ...

• Does your microbiologist discuss infection cases in ICU with you?

1. Each case
2. Few cases
3. Upon asking
4. Never
Asking the question you always wanted to ask ...

- Does your microbiologist gives MIC of antibiotics apart from sensitivity in ICU infections?

1. Each case
2. Few cases
3. upon asking
4. Never
Asking the question you always wanted to ask ...

• Does your microbiologist gives MIC of antibiotics apart from sensitivity in ICU infections?

1. Each case
2. Few cases
3. upon asking
4. Never

No, MIC is not the acronym for "Minimal Interest to the Clinician"!
What did the textbooks say about antibiotic dosages and schedules in the 70’s?

1. Stay above the MIC... but how much?
2. Remain around for a while... but how long?
3. Hope it works... against everything?
4. Hope it is not toxic... can’t do much...
In a nutshell ... so far ...

- Microbiology parameters: MIC!
- **Pharmacodynamic parameters**
- PK/PD as applied to beta-lactams: Time-above MIC
- The problems if you underdose
- Take home message
Pharmacokinetics

Dosage → Serum concentration varying over time

Concentration at the site of infection

Concentration at other sites
Pharmacodynamics

Dosage → Serum concentration varying over time

Concentration at the site of infection → Therapeutic effects

Concentration at other sites → Toxic effects
PK / PD : why does it improve the use of antibiotics?

The basics:

- anti-infective drug usage has long been irrational or not scientifically based on a pharmacodynamic point of view
  - search for low doses for fear of toxicity
  - “errors” in drug dosages at registration
  - misunderstanding of “optimal schedules”

- pharmacokinetics was mostly used to establish “drug presence” rather than to correlate dosing with efficacy

Pharmacodynamics of antiinfective drugs was largely “terra incognita” 20 years ago
How did it start?

A bunch of good guys met in Stockholm in 1989...
What did they think all about?

- Population pharmacokinetics
- Tissue concentrations
- Efficacy/toxicity ratios
- AUIC and fluoroquinolones
- Postantibiotic effect and β-lactam infusion
- Once-daily dosing of aminoglycosides
Pharmacodynamics: influence of time and concentration...

Craig et al.
Pharmacokinetics - Pharmacodynamics

**Pharmacokinetics**
conc vs time

**Pharmacodynamics**
conc vs effect

**PK/PD**
effect vs time

from Derendorf,
ISAP workshop
PK/PD since 1989 ...

1990 ... : organization of sessions on pharmacodynamics at the major international meetings (ICAAC, ECCMID, etc…)

1995 ... : Introduction of PK/PD considerations in the drug development and registration process ... (FDA/EMEA)

2005 ... : PK/PD considerations introduced in clinical investigations and daily clinical activities ...

now .... : PK/PD considerations begin to be used to define optimal reimbursement schemes in Europe …
PK/PD - Potential Benefits

- Facilitate Early Selection of Lead Drug Candidate (e.g., Pre-Clinical Screening)
- Select Appropriate Dosage Regimen (e.g., Phase 1/2)
- Better Understand Clinical / Microbiological Outcome (e.g., Phase 3)
- More Efficient Drug Development Program

http://www.fda.gov/cder/present/anti-infective798/biopharm/index.htm
More questions …

• Do you agree the benefit of HIT HARD HIT FAST?

1. No
2. Yes
More questions …

• Do you agree the benefit of HIT HARD HIT FAST?

Paul Ehrlich:

‘Frapper fort et frapper vite‘ (Hit hard and early) –

Address to the 17th International Congress of Medicine, 1913

And before we continue …

- In How many patients you are implementing HIT HARD HIT FAST with antibiotics?

1. 0%
2. 25%
3. 50%
4. 75%
5. 100%
"Inadequate dosing of antibiotics is probably an important reason for misuse and subsequent risk of resistance.

A recommendation on proper dosing regimens for different infections would be an important part of a comprehensive strategy.

The possibility of approving a dose recommendation based on pharmacokinetic and pharmacodynamic considerations will be further investigated in one of the CPMP* working parties…"

* Committee for Proprietary Medicinal Products – European Medicines Agency
PK / PD in action for science and clinics

Some achievements:

• once-daily dosing of aminoglycosides registration or reregistration in several countries
  • amikacin, netilmicin (from bid to qd)
  • isepamicin (registered essentially for qd dosing)

• 24h AUC / MIC and C_{max} / MIC ratios used as guides for phase II / III trials, for treatment optimization and for registration of new antimicrobials
  • moxifloxacin
  • telithromycin

• Time above MIC as "gold standard" for β-lactams
PK-PD properties of antibiotics

Most available antibiotics can be divided in 3 main groups with respect to PK/PD properties:

- Time-dependent ("T > MIC")
  → β-lactams (all)

- Concentration-dependent ("Cmax / MIC")
  → aminoglycosides and, for eradication, fluroquinolones

- Total daily dose-dependent ("AUC / MIC")
  → fluroquinolones (for global efficacy) and all others
Relationship between peak/MIC and efficacy of cefotaxime towards *Klebsiella pneumoniae* in murine pneumonia (after W.A. Craig *)

![Graph showing the relationship between peak/MIC ratio and Log_{10} CFU per Lung at 24 Hours.](image)

* 2d ISAP Educational Workshop, Stockholm, Sweden, 2000
Relationship between time above MIC (T>MIC) and efficacy of cefotaxime towards *Klebsiella pneumoniae* in murine pneumonia (after W.A. Craig * )

![Graph showing the relationship between time above MIC and log10 CFU per Lung at 24 Hours.](image)

- $R^2 = 94\%$

* 2d ISAP Educational Workshop, Stockholm, Sweden, 2000
In a nutshell ... so far ...

- Microbiology parameters: MIC!
- Pharmacodynamic parameters
- **PK/PD as applied to beta-lactams:** Time-above MIC
- The problems if you underdose
- Take home message
You know it is "time above MIC", but…

- How much / How frequent? (Static dose vs maximum effect?)
- The same for all beta-lactams? (Free fractions of the drug ($F_u$)?)
- The same for all micro-organisms?
- The same for all infections?
- Can you apply to all patients?
Mumbai, 12 February 2011
Strategies to combat resistance: focus on PK/PD

How much time above MIC?

- cefotaxime
- neutropenic mice
- K. pneumoniae
- pulmonary infection

100% - Maximal effect?

Static dose?

$R^2 = 94\%$

$40\%$

Log$_{10}$ cfu per lung at 24 hours

Time above MIC (%)
Here is a proposal ...

Moderately severe infection in a non-immunospressed patient

Severe infection in an immunosuppressed patient

\[ \log_{10} \text{cfu per lung at 24 hours} \]

\[ \text{Time above MIC} (%) \]

100 % ?
The same for all $\beta$-lactams?

Fig. 7. Relationship between the change in log$_{10}$ CFU per thigh or lung for various pathogens following 24 h of therapy with different doses of penicillins (△), cephalosporins (○), and carbapenems (□).


Carbapenems tend to require less time above MIC.
The same for all microorganisms?

T > MIC for static effect

<table>
<thead>
<tr>
<th>Drug</th>
<th>Enterobacteriaceae</th>
<th>S. pneumoniae</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ceftriaxone (free)</td>
<td>38 (34-42)</td>
<td>39 (37-41)</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>38 (36-40)</td>
<td>38 (36-40)</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>36 (27-42)</td>
<td>39 (35-42)</td>
</tr>
<tr>
<td>Cefpirome</td>
<td>35 (29-40)</td>
<td>37 (33-39)</td>
</tr>
<tr>
<td>Meropenem</td>
<td>22 (18-28)</td>
<td></td>
</tr>
<tr>
<td>Imipenem</td>
<td>24 (17-28)</td>
<td></td>
</tr>
</tbody>
</table>
How do you adjust the dose for a given "Time > MIC"?

- "out of the package insert" PK data
- Monte-Carlo simulations and target attainment approaches
### Typical pharmacokinetics of an IV β-lactam

<table>
<thead>
<tr>
<th>time (hours)</th>
<th>serum concentration for 0.5 g</th>
<th>1 g</th>
<th>2 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>25</td>
<td>50</td>
<td>100</td>
</tr>
<tr>
<td>4</td>
<td>12.5</td>
<td>25</td>
<td>50</td>
</tr>
<tr>
<td>6</td>
<td>6</td>
<td>12</td>
<td>25</td>
</tr>
<tr>
<td>8</td>
<td>3</td>
<td>6</td>
<td>12</td>
</tr>
<tr>
<td>10</td>
<td>1.5</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>12</td>
<td>0.75</td>
<td>1.5</td>
<td>3</td>
</tr>
</tbody>
</table>

* Single administration unique; half-life 2h; \( V_d = 0.2 \text{ l/kg} \)
### Reading the labeling (package insert)

<table>
<thead>
<tr>
<th>time (hours)</th>
<th>serum concentration for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.5 g</td>
</tr>
<tr>
<td>2</td>
<td>25</td>
</tr>
<tr>
<td>4</td>
<td>12.5</td>
</tr>
<tr>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>10</td>
<td>1.5</td>
</tr>
<tr>
<td>12</td>
<td>0.75</td>
</tr>
</tbody>
</table>

* Single administration unique; half-life 2h; $V_d = 0.2$ l/kg

Where would you like to be?
Simple optimisation of IV β-lactams for "difficult" organisms

- 2 g every 12 h: T > MIC = 100% if MIC ≤ 3 mg/L!
- 2 g every 8 h: T > MIC = 100% if MIC ≤ 12 mg/L

More frequent administrations is the best way to increase the activity of β-lactams in difficult-to-treat infections...

PK / PD breakpoint for IV β-lactams: MIC < 8 µg/ml
Target Concentration for β-lactams: continuous infusion

- Maximum effect time-kill at 4 x MIC
- Maximum effect in vitro model 4 x MIC
- Effect in endocarditis model 4 x MIC (Xiong et al 1994)
- Effect in pneumonia model dependent on severity of infection


Figure 2 Relationship between concentration of ceftazidime and kill rate

The relationship follows a Hill-type model with a relatively steep curve; the difference between no effect (growth, here displayed as a negative kill rate) and maximum effect is within two to threefold dilutions. The maximum kill rate is attained at around four times the minimum inhibitory concentration (MIC). Modified with permission from [16].
Continuous infusion of β-lactams: an overview...

- The exact role of continuous infusion of β-lactam antibiotics in the treatment of severe infections remains unclear...

- However, increasing evidence is emerging that suggests potential benefits
  - better attainment of pharmacodynamic targets for these drugs
  - More reliable pharmacokinetic parameters in seriously ill patients
  - when the MIC of the pathogen is $\geq 4$ mg/L (empirical therapy where the susceptibility of the pathogen is unknown)

- Clinical data supporting continuous administration are less convincing, but
  - Some studies have shown improved clinical outcomes from continuous infusion
  - none have shown adverse outcomes.
  - clinical and bacteriological advantage are visible in seriously ill patients requiring at least 4 days of antibiotic therapy.

- Seriously ill patients with severe infections requiring significant antibiotic courses ($\geq 4$ days) may be the subgroup that will achieve better outcomes with continuous infusion.

• Do you agree the benefit of Prolonged infusion of beta-lactams antibiotics?

1. Yes
2. No
• Do you practice prolonged infusion of beta-lactams antibiotics?

1. Yes
2. No
• In how many patients you are implementing Prolonged infusion of beta-lactams?

1. 0%
2. 25%
3. 50%
4. 75%
5. 100%
Problems with continuous infusion ...

- Clearance estimates
- Variations in clearance (ICU)
- Volume of distribution (ICU, burned patients, ...)
- Non-linear clearance
- drug instability
Problems with continuous infusion ...

- Clearance estimates
- Variations in clearance (ICU)
- Volume of distribution (ICU, burned patients, ...)
- Non-linear clearance
- **Drug instability**

You may like to monitor the serum levels if MICs $\geq 4$ (also for discontinuous administration)

- temocillin $>$ piperacillin $>$ ceftazidime $>$ cefepime ...

- !! carbapenems are unstable (3-4h max.)
Carbapenems stability

doi:10.1093/jac/dkq044
Advance publication 21 February 2010

Stability of meropenem and doripenem solutions for administration by continuous infusion

Karine Berthoin¹, Cécile S. Le Duff²,
Jacqueline Marchand-Brynaert², Stéphane Carryn¹,³ and Paul M. Tulkens¹*
Carbapenems in 3h infusion: target attainment rate *

* probability of attaining the target of 40% $T > MIC$ by MIC for dmeropenem as a 30-min and 3-h infusion at the simulated dosage regimens

Thus even resistant bugs / bugs with extremely high MIC also can be taken care with prolonged infusion of meropenem.

Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients

S. Christian Cheatham\textsuperscript{a}, Katherine M. Shea\textsuperscript{b}, Daniel P. Healy\textsuperscript{c}, Melissa L. Humphrey\textsuperscript{d}, Megan R. Fleming\textsuperscript{a}, Matthew F. Wack\textsuperscript{e}, David W. Smith\textsuperscript{f}, Kevin M. Sowinski\textsuperscript{d}, Michael B. Kays\textsuperscript{d, +}

\textsuperscript{a} St Francis Hospital, Department of Pharmacy, Beech Grove, IN, USA
\textsuperscript{b} Seton Family of Hospitals, University Medical Center at Brackenridge, Austin, TX, USA
\textsuperscript{c} James L. Winkle College of Pharmacy, University of Cincinnati Academic Health Center, Cincinnati, OH, USA
\textsuperscript{d} Purdue University College of Pharmacy, Department of Pharmacy Practice, 7555 Myers Building, WHS, 1001 West Tenth Street, Indianapolis, IN 46202-2879, USA
\textsuperscript{e} Infectious Diseases of Indiana, Indianapolis, IN, USA
\textsuperscript{f} Clarian Health Partners, Inc., Methodist Hospital, Indianapolis, IN, USA
Fig. 2. Probability of target attainment (PTA) at 60% $fT > \text{MIC}$ for six prolonged infusion regimens of cefepime at specific minimum inhibitory concentrations (MICs). The dotted line indicates a PTA ≥ 90%. $fT > \text{MIC}$, time for which the free drug concentration remains above the MIC; q8h, every 8 h; q12h, every 12 h; q6h, every 6 h.
Table 3
Cumulative fraction of response (%) at 60% $f_t >$ MIC for six prolonged infusion regimens of cefepime against six Gram-negative pathogens.

<table>
<thead>
<tr>
<th>Regimen (infusion time)</th>
<th><em>Escherichia coli</em></th>
<th><em>Klebsiella pneumoniae</em></th>
<th><em>Enterobacter spp.</em></th>
<th><em>Serratia marcescens</em></th>
<th><em>Citrobacter spp.</em></th>
<th><em>Pseudomonas aeruginosa</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>1 g q8h (4 h)</td>
<td>97.7</td>
<td>90.9</td>
<td>97.1</td>
<td>99.1</td>
<td>98.7</td>
<td>88.6</td>
</tr>
<tr>
<td>2 g q8h (4 h)</td>
<td>98.9</td>
<td>95.4</td>
<td>98.9</td>
<td>99.6</td>
<td>99.5</td>
<td>96.2</td>
</tr>
<tr>
<td>1 g q12h (4 h)</td>
<td>96.9</td>
<td>88.6</td>
<td>95.0</td>
<td>98.6</td>
<td>97.1</td>
<td>73.8</td>
</tr>
<tr>
<td>2 g q12h (4 h)</td>
<td>97.8</td>
<td>91.1</td>
<td>97.0</td>
<td>99.1</td>
<td>98.5</td>
<td>87.1</td>
</tr>
<tr>
<td>1 g q6h (3 h)</td>
<td>98.2</td>
<td>92.6</td>
<td>98.0</td>
<td>99.3</td>
<td>99.1</td>
<td>92.7</td>
</tr>
<tr>
<td>2 g q6h (3 h)</td>
<td>99.4</td>
<td>97.5</td>
<td>99.4</td>
<td>99.8</td>
<td>99.7</td>
<td>98.2</td>
</tr>
</tbody>
</table>

$f_t >$ MIC, time for which the free drug concentration remains above the minimum inhibitory concentration of the organism; q8h, every 8 h; q12h, every 12 h; q6h, every 6 h.

Cefepime 1 g q8h infused over 4 h provides optimum target attainment for bacterial pathogens with MICs $\leq$ 8 $\mu$g/mL. However, higher dose regimens may be considered to provide adequate coverage in infections where *P. aeruginosa* is a likely pathogen. After the results of susceptibility testing are known, dosage reductions may be considered without sacrificing adequate pharmacodynamic exposures if the MIC is $\leq$ 2 $\mu$g/mL.
Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: An update to our clinical pathway

Table 1 Revised Hartford Hospital empiric dosing recommendations for cefepime and meropenem in VAP patients based on ability to achieve targeted pharmacodynamic exposures

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dosing recommendations by CrCL (mL/min)</th>
<th>30-49</th>
<th>&lt;30</th>
<th>CRRT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&gt;50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cefepime</td>
<td>2g q8h (3-h INF)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meropenem</td>
<td>2g q8h (3-h INF)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CrCl indicates creatinine clearance calculated by Cockcroft-Gault equation; CRRT, continuous renal replacement therapy; INF, infusion duration.
Clinicians tend to ask only (and clinical microbiologists to provide only) "S – I – R" answers based on accepted breakpoints …

But, what is a breakpoint?
The next slides describe the EUCAST procedure for harmonising European breakpoints and reach rational values.

Clinical breakpoints

Clinical breakpoints are for everyday use in the clinical laboratory to advise on patient therapy.

In EUCAST tables, the I-category is not listed. It is implied as the values between the S-breakpoint and the R-breakpoint.

For a breakpoint listed as S=1 mg/L and R=8 mg/L the intermediate category is 2 - 8 (technically >1 - 8) mg/L.

For a breakpoint listed as S=22 mm and R=18 mm the intermediate category is 18-21 mm.

- clinical breakpoints - bacteria (v 1.1) - pdf-file for printing (April 27, 2010)
- clinical breakpoints - bacteria (v 1.1) - Excel-file for screen (April 27, 2010)
- clinical breakpoints - fungi (MIC breakpoints)
- definitions of clinical breakpoints and epidemiological cut off values
- procedure for harmonizing and defining breakpoints

http://www.eucast.org
The next slides describe the EUCAST procedure for harmonising European breakpoints and reach rational values.
1. Data on dosing, formulations, clinical indications and target organisms are reviewed and differences which might influence breakpoints are highlighted.

2. Multiple MIC-distributions are collected, the wild type MIC distribution is defined and tentative epidemiological cut-off values determined (WT ≤X mg/L).

4. Pharmacokinetic / Pharmacodynamic data are collected and evaluated; Monte Carlo simulations are performed and a PK/PD breakpoint calculated based on conventional dosing regimens.

5. Clinical data relating outcome to MIC-values, wildtype and resistance mechanisms are assessed in relation to the tentative breakpoint.

6. PK/Pd breakpoints are checked against target species wild type MIC distributions to avoid splitting the wild type population.

http://www.eucast.org
7. Tentative breakpoints by the EUCAST Steering Committee are referred to the national breakpoint committees for comments. When steering committee and national committees agree the tentative breakpoints are subjected to the EUCAST consultation process:

8. Consultation process on tentative breakpoints:
   - EUCAST general committee
   - Expert committees (*Neisseria*, Anaerobes, others)
   - Pharmaceutical industry, AST device manufacturer
   - Others via EUCAST website

9. Rationale document prepared and published on website

http://www.eucast.org
The carbapenem breakpoints for Enterobacteriaceae will detect all clinically important resistance mechanisms (including the majority of carbapenemases).

Some strains that produce carbapenemase are categorized as susceptible with these breakpoints and should be reported as tested, i.e. the presence or absence of a carbapenemase does not in itself influence the categorization of susceptibility.

In many areas, carbapenemase detection and characterization is recommended or mandatory for infection control purposes.
### Cephalosporins

<table>
<thead>
<tr>
<th>Cephalosporins</th>
<th>MIC breakpoint (mg/L)</th>
<th>Disk content (μg)</th>
<th>Zone diameter breakpoint (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S ≤</td>
<td>R &gt;</td>
<td>S ≥</td>
</tr>
<tr>
<td>Cefepime</td>
<td>1</td>
<td>4</td>
<td>30</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>1</td>
<td>4</td>
<td>10</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>1</td>
<td>2</td>
<td>30</td>
</tr>
</tbody>
</table>

1. The cephalosporin breakpoints for Enterobacteriaceae will detect all clinically important resistance mechanisms (including ESBL, plasmid mediated AmpC). Some strains that produce beta-lactamases are susceptible or intermediate to 3rd or 4th generation cephalosporins with these breakpoints and should be reported as found, i.e. the presence or absence of an ESBL does not in itself influence the categorization of susceptibility. In many areas, ESBL detection and characterization is recommended or mandatory for infection control purposes.

**EUCAST and cephalosporins**

**Why so low?**

**To exclude ESBL..**
What about ESBL?

Beta-lactamases: Classification

Serine enzymes

Group C
AmpC
TEM / SHV /CTX-M
ESBLs

Group A
TEM / SHV /CTX-M

Group D
OXA

Metallo (Zn) enzymes

Group B
IMP/VIM
Class A and D of $\beta$-lactamases are poorly active on 3d generation cephalosporins

Table 130.1 Functional classification of $\beta$-lactamases

<table>
<thead>
<tr>
<th>Group</th>
<th>Molecular class</th>
<th>Preferred substrates</th>
<th>Active $\beta$-lactams</th>
<th>Typical examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1: serine cephalosporinases not inhibited by clavulanic acid</td>
<td>C</td>
<td>Cephalosporins I and II (&gt;&gt; cephalosporins III, monobactams, penicillins)</td>
<td>Carbapenems, Temocillin, Cephalosporins III and IV; variable upon level of expression</td>
<td>AmpC from gram-negatives; variable upon the species</td>
</tr>
<tr>
<td>2d: cloxacillin-hydrolyzing $\beta$-lactamases generally inhibited by clavulanic acid</td>
<td>D</td>
<td>Penicillins, Cloxacillin, Cephalosporins I and II</td>
<td>Carbapenems, Cephalosporin III, Monobactams*, Piperacillin + tazobactam</td>
<td>OXA-1 to -30, PSE-2 from Enterobacteriaceae and P. aeruginosa. OXA-11 to -19, 28, 32, 45 are ESBLs in P. aeruginosa (R to Ceph 3). OXA-23, -24, -58 are carbapenemases in Acinetobacter baumannii</td>
</tr>
</tbody>
</table>

So, now you are left with the ESBL...

Beta-lactamases: Classification

- Serine enzymes
  - Group A: TEM / SHV / CTX-M
    - ESBLs
  - Group C
  - AmpC
  - Group D
    - OXA
- Metallo (Zn) enzymes
  - Group B
    - IMP/VIM

those should be inhibited by tazobactam
An innovative approach for ESBL... 

- take a 4th generation cephalosporin (cefepime [PM]) ➔ should cover (partly AmpC) and resist to OXA 
- add a β-lactamase inhibitor (tazobactam [TZ]) ➔ will take care of many ESBL

Mouton et al. ICAAC 2010
76 ESBL producing *Enterobacteriaceae* were selected from a variety of clinical specimens.

<table>
<thead>
<tr>
<th></th>
<th>%S</th>
<th>%I</th>
<th>%R</th>
<th>MIC50 (mg/L)</th>
<th>MIC90 (mg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PM</td>
<td>15</td>
<td>14</td>
<td>71</td>
<td>&gt;32</td>
<td>&gt;32</td>
</tr>
<tr>
<td>PM/TZ 1mg/L</td>
<td>41</td>
<td>34</td>
<td>25</td>
<td>2</td>
<td>32</td>
</tr>
<tr>
<td>PM/TZ 4mg/L</td>
<td>70</td>
<td>25</td>
<td>5</td>
<td>0.5</td>
<td>4</td>
</tr>
<tr>
<td>PM/TZ 16mg/L</td>
<td>93</td>
<td>7</td>
<td>0</td>
<td>0,25</td>
<td>1</td>
</tr>
</tbody>
</table>
An innovative approach for ESBL...

Percentage sensitive (S), intermediate (I) and resistant (R)
cefepime (breakpoints EUCAST: ≤1 S – R >8)

Mouton et al. ICAAC 2010
An innovative approach for ESBL...

Cumulative % inhibition of strains with different fixed concentrations of tazobactam.

Mouton et al. ICAAC 2010
An innovative approach for ESBL...

Conclusions:

- The combination of cefepime and tazobactam may offer an alternative treatment option for ESBL harboring strains.

- If the same amount of tazobactam is used as current piperacillin/tazobactam regimens and breakpoint determinations, most strains would be categorized as susceptible.

Mouton et al. ICAAC 2010

In India due to high ESBL: consider cefepime+tazobactam

- **cefepime** 3 x 2 g /day
- **tazobactam** 3 x 0.25 g /day
In a nutshell ... so far ...

- Microbiology parameters: MIC!
- Pharmacodynamic parameters
- PK/PD as applied to beta-lactams: Time-above MIC
- The problems if you underdose
- Take home message
A simple experiment …

Exposure of *E. aerogenes* to anti-Gram (-) penicillin (temocillin) to 0.25 MIC for 14 days with daily readjustment of the concentration based on MIC détermination

<table>
<thead>
<tr>
<th>Strains</th>
<th>Initial</th>
<th>TEM-exposed</th>
<th>Revertant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MIC (mg/L)</td>
<td>MIC (mg/L)</td>
<td>MIC (mg/L)</td>
</tr>
<tr>
<td></td>
<td>TEM</td>
<td>FEP</td>
<td>MEM</td>
</tr>
<tr>
<td>2114/2 c</td>
<td>8</td>
<td>2</td>
<td>0.25</td>
</tr>
<tr>
<td>2502/4 c</td>
<td>8</td>
<td>2</td>
<td>0.125</td>
</tr>
<tr>
<td>3511/1 c</td>
<td>32</td>
<td>2</td>
<td>0.125</td>
</tr>
<tr>
<td>7102/10 d</td>
<td>512</td>
<td>32</td>
<td>1</td>
</tr>
</tbody>
</table>

*a* figures in bold indicate values > the R breakpoint for Enterobacteriaceae (EUCAST for MEM [8] and FEP [4]; BSAC and Belgium for TEM [16])

*b* dot blot applied with antiOmp36 antibody; signal quantified for grey value after subtraction of the signal of a porin-negative strain (ImageJ software); negative values indicate a signal lower than the background

*c* ESBL TEM 24 (+) ; *d* ESBL (-) and AmpC (+) [high level] ; *e* Intermediate (I) according to EUCAST
A simple experiment ...

Exposure of *E. aerogenes* to anti-Gram (-) penicillin (temocillin) to 0.25 MIC for 14 days with daily readjustment of the concentration based on MIC détermination

<table>
<thead>
<tr>
<th>Strains</th>
<th>MIC (mg/L)</th>
<th>TEM-exposed</th>
<th>MIC (mg/L)</th>
<th>Revertant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initial</td>
<td>TEM</td>
<td>FEP</td>
<td>MEM</td>
</tr>
<tr>
<td></td>
<td>TEM</td>
<td>FEP</td>
<td>MEM</td>
<td>TEM</td>
</tr>
<tr>
<td>2114/2 c</td>
<td>8</td>
<td>2</td>
<td>0.25</td>
<td>2048</td>
</tr>
<tr>
<td>2502/4 c</td>
<td>8</td>
<td>2</td>
<td>0.125</td>
<td>8192</td>
</tr>
<tr>
<td>3511/1 c</td>
<td>32</td>
<td>2</td>
<td>0.125</td>
<td>4096</td>
</tr>
<tr>
<td>7102/10 d</td>
<td>512</td>
<td>32</td>
<td>1</td>
<td>16384</td>
</tr>
</tbody>
</table>

a figures in bold indicate values > the R breakpoint for Enterobacteriaceae (EUCAST for MEM [8] and FEP [4]; BSAC and Belgium for TEM [16])

b dot blot applied with antiOmp36 antibody; signal quantified for grey value after subtraction of the signal of a porin-negative strain (ImageJ software); negative values indicate a signal lower than the background

c ESBL TEM 24 (+) ; d ESBL (-) and AmpC (+) [high level] ; e Intermediate (I) according to EUCAST

sub-MIC concentrations create resistance!
And this happens also with biocides

Exposure of *P. aeruginosa* to sub-MIC concentrations of chlorhexidine

Change in MIC of CHX during exposure to 0.5 MIC with daily concentration readjustment

Typical change in colony size and swarming abilities after 13 days of exposure to 0.5 MIC

Tan et al. ECCMID 2011, in press
And in the clinics ?


Contents lists available at ScienceDirect

International Journal of Antimicrobial Agents

journal homepage: http://www.elsevier.com/locate/ijantimicag

In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy

Mickaël Riou a,1, Sylviane Carbonnelle a,2, Laëtitia Avrain a,b, Narcisa Mesaros a,3, Jean-Paul Pirmay c, Florence Bilocq c, Daniel De Vos c,d, Anne Simon e, Denis Piérard f, Frédérique Jacobs g, Anne Dediste h, Paul M. Tulkens a,⁎, Françoise Van Bambeke a, Youri Glupczynski i
What happens during treatment?

- D0: initial isolate
- DL: last isolate obtained
- individual values with geometric mean (95% CI)
- S (lowest line) and R (highest line) EUCAST breakpoints

* p < 0.05 by paired t-test (two-tailed) and Wilcoxon non-parametric test

a p < 0.05 by Wilcoxon non-parametric test only

Note: stratification by time between D0 and DL gave no clue (too low numbers)

Yes, resistance did develop, but we minimized it for meropenem and cefepime.
And what about colistin?

You first need to consider the MIC distribution.

Here are the data of EUCAST for *Pseudomonas*.

![MIC Distribution Chart]

- **Cut-off**
- **4217 observations (12 data sources)**
- **Clinical breakpoints**: S ≤ 4 mg/L, R > 4 mg/L
And what about colistin?

Dosage (colistin methane sulfonate [CMS]): 240 mg every 8h (= 3 x 10^6 UI)

CMS
- $t_{1/2} \sim 2.3$ h,

Colistin:
- $t_{1/2} \sim 14.4$ h.
- $C_{max}$ (pred.)
  - 1st dose: 0.60 mg/L
  - s.s.: 2.3 mg/L.

Problem #1:
Low initial blood levels suggest the necessity of a loading dose

Plachouras et al. AAC 2009; E-pub 11 May
And what about colistin?

Population analysis profiles of K. pneumoniae isolates

Problem #2: Heteroresistance is frequent with colistin

Poudyal et al. JAC 2008; 62:1311-1318
• Retrospective cohort **clinical study of 258 patients**
• **52.3% isolates were polymyxin–only-susceptible**
• Remainder were susceptible to colistin & at least 1 other antibiotic
Patients with polymyxin-only-susceptible infections

Amongst the combinations of colistin with other antibiotics, only Colistin+Meropenem combination was an independent factor (P = 0.017)
• for cure of infection &
• better infection outcome

In how many patients you are implementing Single dose aminoglycosides?

1. 0%
2. 25%
3. 50%
4. 75%
5. 100%
• In how many patients are you implementing Single dose aminoglycosides?

Thank you!

*Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 49–61*

Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin

Paul M. Tulkens

Laboratoire de Chimie Physiologique, Université Catholique de Louvain, and International Institute of Cellular and Molecular Pathology, Brussels, Belgium

In conclusion, these very sensitive tests of nephro- and oto-toxicity suggest that od dosing of amikacin or netilmicin is, if anything, safer than bd or tid dosing.
And what do we do now with toxicity?

We work on polymyxins with the help of Debaditya Das ... from Kolkata!

Comparative analysis of the potential of polymyxin B and gentamicin to cause apoptosis and necrosis in cultured renal LLC-PK1 cells: concentration-dependent studies with incubated and electroporated cells

Oral presentation (Session: "Antimicrobial pharmacology: from bench to bedside" -- Saturday, 7 May 2011: 16:30)
“Take home” message

- dosage is key to success and protection against resistance...
- dosage should match bacterial susceptibility... and knowledge of MIC is essential
- for $\beta$-lactams, get $\text{TIME} > \text{MIC}$ to reach maximal efficacy ... and dose appropriately...
  $\Rightarrow$ 3h infusion of meropenem and cefepime may help
- Use of correct breakpoints will also help in avoiding the use of "weak antibiotics" ... or to decide dosage escalation to avoid emergence of resistance ...
- New combinations tailored to local needs (viz. cefepime + tazobactam) with 3h infusion) are useful ...
WHO statement 2000

The most effective strategy against antibiotic resistance is:

• “to unequivocally destroy microbes”
• “thereby defeating resistance before it starts”

WHO Overcoming Antimicrobial Resistance, 2000
I hope the future will be fine with you...

http://www.isap.org

All slides are available from here

http://www.facm.ucl.ac.be
And a few sights from Belgium...